Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vasculopathy assessment Clear all
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Patients With Heart Disease Not Eligible for Research Protocols

NCT00001458
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 99 Years
Enrollment
7,829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Not applicable Interventional

Mechanisms That Produce the Leg Dysfunction of Claudication & Treatment Strategies

NCT01970332
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Revascularization Surgery, Supervised exercise therapy
Procedure · Other
Lead sponsor
University of Nebraska
Other
Eligibility
Not listed
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 10, 2026, 8:13 AM EDT
Completed No phase listed Observational Results available

Non-invasive Computer-Aided Phenotyping of Vasculopathy

NCT02143102
View directory record Official record
Conditions
Carotid Atherosclerosis, Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Elucid Bioimaging Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Marrero, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 10, 2026, 8:13 AM EDT
Completed No phase listed Observational

Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography

NCT01527344
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03153111
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Phase 2 Interventional

Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure

NCT00651885
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
treprostinil dienthanolmine sustained release, Placebo
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 10, 2026, 8:13 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Noninvasive Evaluation of Cardiac Allograft Vasculopathy

NCT01305382
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Sep 10, 2026, 8:13 AM EDT
Active, not recruiting No phase listed Observational

Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events

NCT06855394
View directory record Official record
Conditions
Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD), Atherosclerosis of Coronary Artery, Atherosclerosis of Arteries of the Extremities, Unspecified, Heart Diseases, Stroke, Venous Thromboembolic Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 10, 2026, 8:13 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

NCT02864953
View directory record Official record
Conditions
Brain Edema, Stroke, Acute
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Phase 2 Interventional Results available

Impact of Evolocumab in Cardiac Transplant Patients With CAV

NCT03944577
View directory record Official record
Conditions
Heart Transplant
Interventions
Evolocumab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

NCT01410331
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
JVS-100(4 mg) or placebo/8 injections, JVS-100(8 mg) or placebo/8 injections, JVS-100(8 mg) or placebo/16 injections, JVS-100(16 mg) or placebo/16 injections
Biological
Lead sponsor
Juventas Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

NCT05704725
View directory record Official record
Conditions
Chorioretinal Vascular Disease
Interventions
ABP 938, Aflibercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Austin, Texas • Bellaire, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

NCT00120406
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
Zilver® PTX™ Drug Eluting Vascular Stent, Angioplasty
Device · Procedure
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
44
States / cities
Mountain View, California • Oceanside, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 10, 2026, 8:13 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Brain Imaging for HIV-Associated Thinking and Mood Disorders

NCT01692236
View directory record Official record
Conditions
Human Immunodeficiency Virus, Neurocognitive Impairment
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
25 Years to 61 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

NCT01486446
View directory record Official record
Conditions
Primary Erythromelalgia, Inherited Erythromelalgia
Interventions
XPF-002, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
19 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Not applicable Interventional Results available

A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.

NCT02080871
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Stenting of the Common and/or External Iliac Arteries
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 10, 2026, 8:13 AM EDT
Terminated Not applicable Interventional

Diamondback in Peripheral Vascular Disease

NCT03455374
View directory record Official record
Conditions
Peripheral Vascular Diseases, Critical Limb Ischemia
Interventions
Treatment with CSI atherectomy device
Device
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 10, 2026, 8:13 AM EDT
Recruiting Not applicable Interventional

WEARABLE-BP: Wearable Everyday Automated Readings to Enable Assessment of Blood Pressure Control

NCT07523269
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Aktiia G1 BP monitor for 12 months, Traditional BP monitor for 6 months / Aktiia G1 BP monitor for 6 months
Device
Lead sponsor
Aktiia SA
Industry
Eligibility
21 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 10, 2026, 8:13 AM EDT
Terminated Phase 1 Interventional

Cardiac Allograft Remodeling and Effects of Sirolimus

NCT01889992
View directory record Official record
Conditions
Cardiac Hypertrophy, Immunosuppression
Interventions
Cardiac MRI, Coronary angiography with IVUS, Cardiac Allograft Remodeling, M-TOR Immunosuppression, Cardiac Biopsy C4D stain, Genetic Mechanism of M-TOR, Cardiopulmonary Exercise Test (CPET)
Radiation · Procedure · Other + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 10, 2026, 8:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis

NCT03122873
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 10, 2026, 8:13 AM EDT
Not listed Phase 2 Interventional

BFPET for Regional Myocardial Perfusion Imaging

NCT02252783
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
BFPET
Drug
Lead sponsor
Fluoropharma, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 10, 2026, 8:13 AM EDT
Completed Phase 2 Interventional Results available

ACP-01 in Patients With Critical Limb Ischemia

NCT02551679
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
ACP-01, Placebo
Biological
Lead sponsor
Hemostemix
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
16
States / cities
Sacramento, California • Aurora, Colorado • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 10, 2026, 8:13 AM EDT
Completed No phase listed Observational

Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant

NCT01403142
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 10, 2026, 8:13 AM EDT